Markman M - Search Results

1

Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.

Markman M, Kennedy A, Kim J. Markman M, et al. Gynecol Oncol. 2001 Dec;83(3):593-5. doi: 10.1006/gyno.2001.6432. Gynecol Oncol. 2001. PMID: 11733977

2

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.

Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Connelly E, et al. Among authors: markman m. Gynecol Oncol. 1996 Aug;62(2):166-8. doi: 10.1006/gyno.1996.0210. Gynecol Oncol. 1996. PMID: 8751544 Clinical Trial.

3

Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. Gynecol Oncol. 1996 Mar;60(3):435-7. doi: 10.1006/gyno.1996.0069. Gynecol Oncol. 1996. PMID: 8774653 Clinical Trial.

4

Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis.

Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Markman M, et al. J Cancer Res Clin Oncol. 1997;123(4):224-6. doi: 10.1007/BF01240319. J Cancer Res Clin Oncol. 1997. PMID: 9177495 Clinical Trial.

5

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. Gynecol Oncol. 1997 Jun;65(3):434-6. doi: 10.1006/gyno.1997.4708. Gynecol Oncol. 1997. PMID: 9190971

6

Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-26-S15-29. Semin Oncol. 1997. PMID: 9346218

7

Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. J Cancer Res Clin Oncol. 1998;124(6):326-8. doi: 10.1007/s004320050177. J Cancer Res Clin Oncol. 1998. PMID: 9692840

8

Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.

Markman M, Lichtman SM, Homesley H, Kennedy A, Webster K, Ernst S, Omura G, Belinson J. Markman M, et al. Gynecol Oncol. 1998 Jul;70(1):123-6. doi: 10.1006/gyno.1998.5044. Gynecol Oncol. 1998. PMID: 9698488 Clinical Trial.

9

Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.

Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Xu Y, et al. Among authors: markman m. JAMA. 1998 Aug 26;280(8):719-23. doi: 10.1001/jama.280.8.719. JAMA. 1998. PMID: 9728644

10

Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.

Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, Kulp B, Belinson J. Markman M, et al. Gynecol Oncol. 1998 Aug;70(2):272-4. doi: 10.1006/gyno.1998.5065. Gynecol Oncol. 1998. PMID: 9740704 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

815 results

Search Page

Filters